History - March 2003. Establishment of Braintropia Co., Ltd.- August 2000. Establishment of its Anyang Factory- October 2000. Started producing BT-11. - May 2002. Launched BT-11.- September 2002. Launched its BT-11 capsule- March 2003. Signed a Business Agreement with Dongwon F & B Co., Ltd. Company Vision - To develop a cerebrovascular medicine- To develop an Alzheimer&＃39;s disease medicine - To develop a memory cure medicine - Gene Line Therapy - Resuscitation Accelerating Therapy for Brain Injury- Pursuing mankind&＃39;s happiness and improving quality of life through the development of vaccines Manpower - CEO&＃39;s high level of domestic and international recognition and reliability in neurological circles and the public- Rational organization composed of core research personnel in each field of Alzheimer&＃39;s disease-related research Technology - To develop new medicines and accumulate know-how based on mechanisms at the outbreak of Alzheimer&＃39;s disease- To retain endothelial progenitor cell transplantation and gene line therapy - 4 Patent Registrations, 2 Patent Applications Management - To build a stable management base with investments at the initial stage- To establish a core base for basic researches by utilizing a large-scale research budget backed by the government- To secure efficiency and flexibility through active outsourcing Marketing - To successfully enter the market at an early stage by forging business agreements with Ilyang Pharmaceuticals Co., Ltd. and other companies that have high name recognition- To secure distribution channels through strategic business cooperation in development projects - To conduct active promotion activities through the press, papers, seminars, and website